Research database
SVF Research Library
Search 52,792 real PubMed studies on SVF and adipose-derived stem cells — 38 matching records.
38 results — page 1 of 2
- Level CProspective StudyEurope PMC
Identification of Notch pathway-related biomarkers in patients with idiopathic pulmonary fibrosis
Prospective Study, published in PLoS One (2026) — summary generated from the PubMed abstract.
- 2026
PLoS One - Level DAnimal StudyPubMed
Therapeutic Efficacy of Adipose-Derived Stem Cells for Bleomycin-Induced Idiopathic Pulmonary Fibrosis: A Comparative Study of Intravenous versus Intratracheal Administration.
Animal Study on Systemic / IV, published in Cell J (2026) — summary generated from the PubMed abstract.
- 2026
Cell J - Level DAnimal StudyPubMed
Combinational Therapy of Mesenchymal Stem Cells and Metformin in Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rat Model.
Animal Study on Chronic Inflammation, published in Appl Biochem Biotechnol (2025) — summary generated from the PubMed abstract.
- 2025
Appl Biochem Biotechnol - Level BClinical TrialPubMed
Advances in the research and application of stem cell therapies for idiopathic pulmonary fibrosis.
Clinical Trial on Scar, Chronic Inflammation, published in Am J Clin Exp Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Am J Clin Exp Immunol - Level DNarrative ReviewEurope PMC
Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers
Narrative Review, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.
- 2024
Int J Mol Sci9 citations - Level BClinical TrialEurope PMC
Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects
Clinical Trial, published in Am J Stem Cells (2024) — summary generated from the PubMed abstract.
- 2024
Am J Stem Cells3 citations - Level DNarrative ReviewEurope PMC
Revisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis
Narrative Review on Face & Skin, published in Front Cell Dev Biol (2024) — summary generated from the PubMed abstract.
- 2024
Front Cell Dev Biol10 citations - Level DNarrative ReviewEurope PMC
Persistent microbial infections and idiopathic pulmonary fibrosis - an insight into <i>non-typeable Haemophilus influenza</i> pathogenesis
Narrative Review on Scar, Chronic Inflammation, published in Front Cell Infect Microbiol (2024) — summary generated from the PubMed abstract.
- 2024
Front Cell Infect Microbiol3 citations - Level CProspective StudyPubMed
Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients.
Prospective Study, published in Cells (2024) — summary generated from the PubMed abstract.
- 2024
Cells3 citations - Level DNarrative ReviewEurope PMC
Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis
Narrative Review on Chronic Inflammation, published in Pharm Sci Adv (2024) — summary generated from the PubMed abstract.
- 2024
Pharm Sci Adv - Level CProspective StudyPubMed
Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.
Prospective Study on Scar, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.
- 2022
Stem Cell Res Ther - Level DNarrative ReviewEurope PMC
The Role of Extracellular Vesicles in Idiopathic Pulmonary Fibrosis Progression: An Approach on Their Therapeutics Potential
Narrative Review, published in Cells (2022) — summary generated from the PubMed abstract.
- 2022
Cells14 citations - Level AMeta-analysisEurope PMC
Inflammatory bowel disease and risk of idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis
Meta-analysis on Hip, published in PLoS One (2022) — summary generated from the PubMed abstract.
- 2022
PLoS One - Level DAnimal StudyPubMed
Therapeutic effect of adipose-derived mesenchymal stem cells (AD-MSCs) compared to pirfenidone on corticosteroid resistance in a mouse model of acute exacerbation of idiopathic pulmonary fibrosis.
Animal Study, published in Histol Histopathol (2022) — summary generated from the PubMed abstract.
- 2022
Histol Histopathol5 citations - Level DNarrative ReviewEurope PMC
Mesenchymal Stem Cell-Derived Extracellular Vesicles as Idiopathic Pulmonary Fibrosis Microenvironment Targeted Delivery
Narrative Review, published in Cells (2022) — summary generated from the PubMed abstract.
- 2022
Cells15 citations - Level BClinical TrialEurope PMC
Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis
Clinical Trial, published in Cells (2022) — summary generated from the PubMed abstract.
- 2022
Cells14 citations - Level BClinical TrialEurope PMC
Mesenchyme Stem Cell-Derived Conditioned Medium as a Potential Therapeutic Tool in Idiopathic Pulmonary Fibrosis
Clinical Trial on Cardiovascular Disease, Immune Modulation, published in Biomedicines (2022) — summary generated from the PubMed abstract.
- 2022
Biomedicines7 citations - Level DNarrative ReviewEurope PMC
Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra
Narrative Review, published in Br J Pharmacol (2021) — summary generated from the PubMed abstract.
- 2021
Br J Pharmacol34 citations - Level DNarrative ReviewEurope PMC
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Narrative Review on Scar, published in Pharmacol Ther (2021) — summary generated from the PubMed abstract.
- 2021
Pharmacol Ther482 citations - Level CProspective StudyPubMed
Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis.
Prospective Study on Face & Skin, published in Stem Cell Res Ther (2021) — summary generated from the PubMed abstract.
- 2021
Stem Cell Res Ther45 citations - Level DNarrative ReviewEurope PMC
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
Narrative Review on Immune Modulation, published in Front Immunol (2021) — summary generated from the PubMed abstract.
- 2021
Front Immunol68 citations - Level DNarrative ReviewEurope PMC
Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Narrative Review on Chronic Wound, published in Am J Respir Cell Mol Biol (2021) — summary generated from the PubMed abstract.
- 2021
Am J Respir Cell Mol Biol50 citations - Level DNarrative ReviewEurope PMC
Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution
Narrative Review on Immune Modulation, published in Front Pharmacol (2021) — summary generated from the PubMed abstract.
- 2021
Front Pharmacol29 citations - Level DAnimal StudyPubMed
Conditioned medium from a human adipose-derived stem cell line ameliorates inflammation and fibrosis in a lung experimental model of idiopathic pulmonary fibrosis.
Animal Study, published in Life Sci (2021) — summary generated from the PubMed abstract.
- 2021
Life Sci12 citations
In-depth reviewed studies (full Thai translation)
Evidence system- Level ARandomized Controlled Trial
Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial
A multicentre randomized trial in 480 knee osteoarthritis patients comparing SVF, BMAC and umbilical cord MSCs against corticosteroid injection. At 12 months no cell product outperformed the steroid control.
- 2023
- United States
- n = 480
- Level AMeta-analysis
Intra-articular Injection of Autologous Adipose-Derived Stem Cells or Stromal Vascular Fractions: Are They Effective for Patients With Knee Osteoarthritis? A Systematic Review With Meta-analysis of Randomized Controlled Trials
Pooled five RCTs comparing ADSC/SVF injection with placebo or hyaluronic acid, finding significant pain and function improvement at 6 and 12 months.
- 2023
- South Korea
- Level AMeta-analysis
Rapid-acting pain relief in knee osteoarthritis: autologous-cultured adipose-derived mesenchymal stem cells outperform stromal vascular fraction: a systematic review and meta-analysis
Analysed 31 studies with 1,406 patients: cultured ADMSCs reduced pain from month 3, whereas SVF reached significance only at 12 months.
- 2024
- South Korea
- n = 1406